Skip to main navigation
Skip to search
Skip to main content
The Hebrew University of Jerusalem Home
Approve / Request updates on publications
Link opens in a new tab
Search content at The Hebrew University of Jerusalem
Home
Profiles
Research units
Research output
Prizes
Hepatic effects of rosiglitazone in rats with the metabolic syndrome
Zvi Ackerman
*
, Mor Oron-Herman
, Orit Pappo
, Edna Peleg
,
Rifaat Safadi
, Hemda Schmilovitz-Weiss
, Maria Grozovski
*
Corresponding author for this work
Research output
:
Contribution to journal
›
Article
›
peer-review
32
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Hepatic effects of rosiglitazone in rats with the metabolic syndrome'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Metabolic Syndrome
100%
High-fructose Diet
100%
Rosiglitazone
100%
Hepatic Effects
100%
Hepatic Fibrosis
33%
Microvesicular Steatosis
33%
One-group
16%
Adiponectin
16%
Phospholipids
16%
Blood Pressure
16%
Serum Triglycerides
16%
Antioxidant Activity
16%
Hepatic Lipid Metabolism
16%
Plasma Parameters
16%
Dietary Groups
16%
Non-alcoholic Fatty Liver Disease (NAFLD)
16%
Chow Diet
16%
Paraoxonase-1 Activity
16%
Glutathione Reductase
16%
Tocopherol Content
16%
Total Lipids
16%
Hepatic Fat
16%
Reductase Activity
16%
Favorable Effect
16%
Hepatic Malondialdehyde
16%
Pharmacology, Toxicology and Pharmaceutical Science
Metabolic Syndrome X
100%
Rosiglitazone
100%
Rat
100%
Fructose
85%
Triacylglycerol
28%
Liver Fibrosis
28%
Lipid
28%
Steatosis
28%
Antioxidant
14%
Phospholipid
14%
Malonaldehyde
14%
Tocopherol
14%
Nonalcoholic Fatty Liver
14%
Adiponectin
14%
Aryldialkylphosphatase
14%
Glutathione Reductase
14%